EP
KROS icon

Eversept Partners’s Keros Therapeutics KROS Stock Holding History

Eversept Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-27,631
Closed -$1.7M – 99
2021
Q1 		$1.7M Buy
+27,631
New +$1.75M 0.13% 67

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Eversept Partners's KROS Position: Q2 2021 in Review

Eversept Partners sold out of Keros Therapeutics (KROS) in Q2 2021, closing a stake of 27,631 shares — an estimated $1.7M sold.

Eversept Partners first reported a position in KROS in Q1 2021 and held it in 1 quarter. The position peaked at $1.7M in Q1 2021. 80 funds tracked by Wall St. Rank hold KROS as of Q2 2021.

  • Eversept Partners reported no remaining Keros Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Eversept Partners sold 27,631 Keros Therapeutics shares in Q2 2021, an estimated $1.7M.
  • Eversept Partners first reported a position in Keros Therapeutics in Q1 2021 and held it in 1 quarter.
  • Eversept Partners's Keros Therapeutics position peaked at $1.7M in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2021.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.